{
    "nctId": "NCT04967248",
    "briefTitle": "A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting",
    "officialTitle": "Alpelisib (Piqray\u00ae) Post-Authorization Safety Study (PASS): a Non-interventional Study of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-), Locally Advanced or Metastatic Breast Cancer With a Phosphatidylinositol-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting",
    "overallStatus": "RECRUITING",
    "conditions": "Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Incidence proportion of hyperglycemia",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent from the patient or a legally acceptable representative, obtained before any study-related activities are undertaken\n* Patients diagnosed with HR+, HER2- locally advanced or metastatic breast cancer with a PIK3CA mutation\n* Patients who have disease progression following endocrine therapy as monotherapy\n* Patients must be postmenopausal women, or men, \u226518 years of age\n* Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant\n\nExclusion Criteria:\n\n* Use of alpelisib prior to signing the informed consent form for this study\n* Participation in an interventional study within 30 days prior to the initiation of alpelisib",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}